DUBLIN--(BUSINESS WIRE)--The "Cardiovascular Drugs Market Global Briefing 2017" report has been added to Research and Markets' offering.
The global cardiovascular drugs market is expected to reach over $135 billion in 2020
The forecasted growth in this market can be attributed to the increase in aging population, increase in the prevalence of cardiovascular diseases and availability of more generic drugs that reduce the cost of treatment.
Cardiovascular drugs market covers the drugs used to treat conditions that affect the heart or blood vessels. These conditions include heart stroke, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Some of the major cardiovascular drugs include anti-hypertensive drugs such as calcium channel blockers and Angiotensin II receptor antagonists, and hypolipidemic drugs such as fibric acid derivatives and bile acid binding resins.
Novel Oral Anti-coagulants (NOACs) To Prevent Thrombosis - NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases.
Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration xxviii. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb.
Scope:
- Markets Covered: Anti-hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases.
- Time Series: Five years historic and forecast.
- Data: Market value in $ billions.
- Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Merck & Co.
- Sanofi
- Pfizer
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly
- Johnson & Johnson
- AstraZeneca PLC
- Abbott Laboratories Inc.
- Bayer AG
For more information about this report visit https://www.researchandmarkets.com/research/g6r3lk/global?w=4
